Mark Cuban: GLP1 drug prices affected by PBM and carrier system manipulation

Mark Cuban: GLP1 drug prices affected by PBM and carrier system manipulation
Cuban questions GLP1 pricing model

Mark Cuban is addressing the ongoing debate surrounding the cost of GLP1 drugs in the U.S.

Cuban argues that consumer shopping is unlikely to lower prices when most pharmacies must purchase medications at near-retail rates, due to conditions set by major pharmacy benefit managers (PBMs) and insurance carriers. He asserts these industry practices have restricted certain medications, like GLP1 drugs, from being priced competitively outside the established PBM and carrier systems.

Cuban's comments come as stakeholders across the pharmaceutical sector continue to discuss the root causes of persistently high drug prices in the U.S. market.

Cuban has previously raised concerns about transparency in U.S. government VA pharmacy pricing and contract disclosure efforts, according to a prior report. He has also flagged high healthcare costs as a challenge for both employee affordability and employer hiring decisions, as noted in a separate article. His recent comments add to ongoing discussion of systemic pricing issues in the drug industry.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.